Developer docs
API playgroundTry for free, no card

Search company profiles

Premier Biotech

Full company profile

uuid0007yw6

Namestring
Premier Biotech
Legal namestring
Premier Biotech, LLC.
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Premier Biotech, LLC is a Minneapolis-based private drug testing diagnostics and laboratory services company founded in 2006 and backed by private equity firm Align Capital Partners since November 2022. The company manufactures point-of-collection rapid oral fluid and urine drug tests (notably OralTox, recognized as the #1 brand in rapid oral fluid testing per Current Consulting Group's 27th Annual Drug Testing Industry Survey), complementary products such as Premier Bio-Cup, Premier Bio-Dip, the Intercept i2he oral fluid collection device, and SAFE harm reduction test strips detecting fentanyl, xylazine, nitazenes, and benzodiazepines. Premier Biotech's OT-Scan digital platform automatically interprets rapid test results and produces laboratory-style reporting within minutes, while CAP-accredited forensic and SAMHSA-certified laboratories in Minneapolis and Scottsdale provide confirmatory testing for regulated programs.

The company serves employers, government agencies, healthcare providers, and background screening partners across Workplace, Government, and Clinical/Healthcare verticals, with international reach into Australia and New Zealand via the NexScreen acquisition. Premier Biotech generates revenue through one-time product sales of rapid testing kits, recurring/subscription revenue from OT-Scan and Premier Biotech Services (PBS) program administration, professional services revenue from confirmatory lab testing, and e-commerce/transaction revenue through its TransMed distribution platform. Pricing is quote-based with multi-year enterprise and government contracts; no public pricing or revenue figures are disclosed.

Since partnering with ACP, Premier Biotech has executed an active buy-and-build strategy, completing eight acquisitions including Desert Tox (June 2024, SAMHSA-certified lab), National Test Systems (November 2025, government and behavioral health), GH Solutions (April 2026, distribution), and NexScreen and TransMed (June 2026, international reach and e-commerce). The combined platform positions the company as an integrated provider spanning collection, digital interpretation, laboratory confirmation, and program management, with regulatory certifications (CAP, SAMHSA, CLIA-waived, 510(k)-cleared) forming the compliance backbone for federal, state, and clinical testing programs.

Short descriptiontext

Premier Biotech manufactures rapid oral fluid and urine drug testing kits, the OT-Scan digital interpretation platform, and operates CAP-accredited, SAMHSA-certified laboratories. It serves employers, government agencies, healthcare providers, and background screening partners across the United States, Australia, and New Zealand.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMinneapolis, United States
HQ citystring
Minneapolis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug testing diagnostics, oral fluid testing, laboratory testing services, point-of-care testing, workplace drug screening
Industry2 codes
PRIMARYHLAHAOAG
Drug-of-Abuse & Toxicology Rapid Tests (Urine/saliva panels)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAFAMAB
Clinical Chemistry & Immunoassay Laboratories
NAICS code2 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Drug Testing Diagnostics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Rapid Testing Products
TypeOne Time License
Description

Sales of point-of-care rapid drug testing products including OralTox oral fluid tests, Premier Bio-Cup and Premier Bio-Dip urine tests, and SAFE harm reduction test strips. Products are sold directly to employers, government agencies, and healthcare providers.

premierbiotech.com
2Laboratory Testing Services
TypeProfessional Services
Description

Confirmation testing services provided through CAP-accredited forensic and SAMHSA-certified laboratories in Minneapolis and Scottsdale. Supports regulated programs requiring chain-of-custody procedures.

premierbiotech.com
3Technology and Software Services
TypeSubscription Recurring
Description

Digital platform services including OT-Scan app for automated result interpretation and reporting, and Premier Biotech Services (PBS) for program administration, reporting, and background screening management.

premierbiotech.com
4E-commerce Distribution
TypeTransaction Fee
Description

Through acquired companies like TransMed, Premier operates e-commerce platforms distributing testing products and laboratory supplies to over 1,000 direct customer accounts.

financialcontent.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Quote-based pricing for enterprise and government customers
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is quote-based / not publicly disclosed. Customers contact sales team for custom pricing based on volume, testing panels, and service requirements.

premierbiotech.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1OralTox
Description

Point-of-collection oral fluid test, recognized as the #1 brand in rapid oral fluid drug testing.

premierbiotech.com
+6 more records
Core offering1 text field

Premier Biotech manufactures and supplies rapid drug testing diagnostic devices including oral fluid and urine tests, complemented by digital interpretation tools and SAMHSA-certified/CAP-accredited laboratory confirmation services. The company serves employers, government agencies, healthcare providers, and background screening partners with an integrated testing ecosystem covering collection, interpretation, and confirmation from a single sample.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • OT-Scan automatically interprets results, delivering consistent laboratory-style reporting within minutes
+1 more record
Product overview1 text field

Premier Biotech operates as an integrated drug and alcohol testing platform combining point-of-collection rapid tests with digital interpretation technology and laboratory confirmation services. The core product portfolio includes OralTox® (the #1 recognized rapid oral fluid testing brand), OT-Scan® (digital results reading and reporting app), Premier Bio-Cup and Premier Bio-Dip (rapid urine testing products), SAFE Harm Reduction Testing (adulterant detection strips), and Intercept i2he® (oral fluid collection device). These are supported by CAP-accredited forensic and SAMHSA-certified laboratory services in Minneapolis and Scottsdale, plus Premier Biotech Services (PBS) for end-to-end program management. The company has pursued an active acquisition strategy since partnering with Align Capital Partners in November 2022, acquiring Desert Tox LLC (SAMHSA-certified lab), National Test Systems (drug screening supplies), GH Solutions (point-of-care diagnostics distributor), and NexScreen/TransMed (point-of-care diagnostics and e-commerce testing supplies) to expand its footprint across workplace, government, and clinical markets.

Product and service9 records
1OralTox
CategoryDrug Testing Diagnostics
Description

Rapid oral fluid drug test for use by employers, government agencies, healthcare providers, and background screening partners. Observed collection makes it nearly impossible to cheat, with results in minutes.

2OT-Scan
CategoryDrug Testing Software
Description

Digital interpretation app that objectively reads OralTox test results to reduce human error and produce defensible records. Used by collectors and program administrators.

3Premier Bio-Cup
CategoryDrug Testing Diagnostics
Description

Urine drug test cup for use in workplace, clinical, and government drug screening programs.

4Premier Bio-Dip
CategoryDrug Testing Diagnostics
Description

Urine drug test dip card for rapid screening applications.

5SAFE Harm Reduction Testing
CategoryHarm Reduction Diagnostics
Description

Single-use fentanyl and xylazine test strip used for harm reduction testing.

6Intercept i2he
CategorySample Collection Devices
Description

Oral fluid collection device used for laboratory-based oral fluid drug testing programs.

7Premier Identification Kit (PIK)
CategoryDrug Testing Supplies
Description

Identification kit used to support donor identification and chain-of-custody procedures in drug testing programs.

8Lab Services
CategoryLaboratory Services
Description

SAMHSA-certified and CAP-accredited laboratory confirmation services that produce defensible results for regulated drug testing programs.

9Premier Biotech Services (PBS)
CategoryCustomer Service and Logistics
Description

Customer service and logistics offering that simplifies test ordering and shipping for customers, with same-day shipping on most orders placed before 2 PM CT.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeOthersAnnounced on2026-06-01
Description

NexScreen provides point-of-care diagnostic products across the United States, Australia, and New Zealand. The acquisition expands Premier's drug and alcohol testing platform with new distribution channels and international reach.

Strategic tierCoreTypeOthersAnnounced on2026-06-01
Description

TransMed offers drug testing products and laboratory supplies to over 1,000 direct customer accounts through an e-commerce platform and international distributor network. The acquisition strengthens Premier's global footprint and online presence.

Strategic tierCoreTypeOthersAnnounced on2026-04-01
Description

GH Solutions is a distributor of point-of-care diagnostic testing products serving government and workplace end markets across the United States. The acquisition increases Premier's customer base and broadens its solution portfolio.

Strategic tierCoreTypeOthersAnnounced on2025-11-01
Description

National Test Systems is a provider of diagnostic drug screening supplies and services across the United States. The acquisition enhances Premier's customer base and strengthens its position in Government and Behavioral Health markets.

Strategic tierCoreTypeOthersAnnounced on2024-06-01
Description

Desert Tox is a SAMHSA-certified laboratory testing services provider acquired by Premier Biotech as its first add-on since being acquired by ACP in November 2022. Desert Tox serves various markets across the U.S. and aims to expand Premier's services and customer base.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Point-of-care diagnostic developer with rapid test products including drug testing panels. Comparable at the rapid test/device technology layer, though smaller and more emerging than Premier's established OralTox platform.

TypeDirect peer
Description

Direct competitor in rapid point-of-care drug testing products including oral fluid and urine panels marketed to employers and resellers. Comparable product overlap with Premier's Premier Bio-Cup/Bio-Dip and OralTox lines at the rapid test/distribution layer.

TypeDirect peer
Description

Manufacturer of DrugTest 5000 and related oral fluid drug testing instruments widely used by law enforcement and workplace programs. Comparable on the rapid oral fluid instrument/consumable side of the market, particularly in criminal justice and European markets.

TypeBroad incumbent
Description

Operates a large rapid diagnostics portfolio including point-of-care drug testing products (e.g., SoToxa oral fluid test). Comparable as a competing rapid oral fluid platform with deeper R&D and global distribution, though drug testing is one of many diagnostic categories within Abbott.

TypeBroad incumbent
Description

Largest U.S. clinical laboratory operator with a dedicated employer services/workplace drug testing business (Quest Diagnostics Employer Solutions). Comparable because it serves the same workplace and clinical drug testing buyers through a national lab network, though its scale and breadth vastly exceed Premier Biotech.

TypeDirect peer
Description

Direct peer in rapid oral fluid drug testing — maker of Intercept Oral Fluid Drug Test and the Quantisal collection device used by many employers and criminal justice programs. Closest like-for-like competitor to OralTox and Intercept i2he, with an established federal/criminal justice footprint.

TypeBroad incumbent
Description

Operates clinical and forensic toxicology testing services (including its Pharmaco and CEDIA toxicology franchises) that compete with Premier's lab confirmation services. Comparable on lab-based drug confirmation, with substantially broader life-sciences scale.

TypeDirect peer
Description

Forensic and clinical toxicology lab serving workplace, legal, and clinical customers. Comparable to Premier's CAP-accredited/SAMHSA-certified lab services in Minneapolis and Scottsdale, competing on turnaround time, panel breadth, and chain-of-custody.

TypeBroad incumbent
Description

National clinical laboratory with employer drug testing services and SAMHSA-certified confirmation capabilities. Comparable on the lab confirmation side of Premier's integrated workflow, though Labcorp competes at much broader scale across routine clinical diagnostics as well.

TypeDirect peer
Description

Specialist in workplace drug testing — though focused on hair testing rather than oral fluid. Comparable as a niche, employer-focused drug testing provider competing for similar workplace and government customers with a differentiated specimen type.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Premier Biotech

Drug Testing Diagnosticsinnovation.premierbiotech.com

Premier Biotech manufactures rapid oral fluid and urine drug testing kits, the OT-Scan digital interpretation platform, and operates CAP-accredited, SAMHSA-certified laboratories. It serves employers, government agencies, healthcare providers, and background screening partners across the United States, Australia, and New Zealand.

What Premier Biotech does

Premier Biotech, LLC is a Minneapolis-based private drug testing diagnostics and laboratory services company founded in 2006 and backed by private equity firm Align Capital Partners since November 2022. The company manufactures point-of-collection rapid oral fluid and urine drug tests (notably OralTox, recognized as the #1 brand in rapid oral fluid testing per Current Consulting Group's 27th Annual Drug Testing Industry Survey), complementary products such as Premier Bio-Cup, Premier Bio-Dip, the Intercept i2he oral fluid collection device, and SAFE harm reduction test strips detecting fentanyl, xylazine, nitazenes, and benzodiazepines. Premier Biotech's OT-Scan digital platform automatically interprets rapid test results and produces laboratory-style reporting within minutes, while CAP-accredited forensic and SAMHSA-certified laboratories in Minneapolis and Scottsdale provide confirmatory testing for regulated programs.

The company serves employers, government agencies, healthcare providers, and background screening partners across Workplace, Government, and Clinical/Healthcare verticals, with international reach into Australia and New Zealand via the NexScreen acquisition. Premier Biotech generates revenue through one-time product sales of rapid testing kits, recurring/subscription revenue from OT-Scan and Premier Biotech Services (PBS) program administration, professional services revenue from confirmatory lab testing, and e-commerce/transaction revenue through its TransMed distribution platform. Pricing is quote-based with multi-year enterprise and government contracts; no public pricing or revenue figures are disclosed.

Since partnering with ACP, Premier Biotech has executed an active buy-and-build strategy, completing eight acquisitions including Desert Tox (June 2024, SAMHSA-certified lab), National Test Systems (November 2025, government and behavioral health), GH Solutions (April 2026, distribution), and NexScreen and TransMed (June 2026, international reach and e-commerce). The combined platform positions the company as an integrated provider spanning collection, digital interpretation, laboratory confirmation, and program management, with regulatory certifications (CAP, SAMHSA, CLIA-waived, 510(k)-cleared) forming the compliance backbone for federal, state, and clinical testing programs.

Premier Biotech firmographics

Firmographics
Name
Premier Biotech
Legal name
Premier Biotech, LLC.
Website
https://innovation.premierbiotech.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
51–100 employees
Short description
Premier Biotech manufactures rapid oral fluid and urine drug testing kits, the OT-Scan digital interpretation platform, and operates CAP-accredited, SAMHSA-certified laboratories. It serves employers, government agencies, healthcare providers, and background screening partners across the United States, Australia, and New Zealand.
Ownership category
akta.pro rank

Premier Biotech industry classification

Industry
Product category
Drug Testing Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAOAG
Drug-of-Abuse & Toxicology Rapid Tests (Urine/saliva panels)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAFAMAB
Clinical Chemistry & Immunoassay Laboratories

Keywords

  • Drug testing diagnostics
  • Oral fluid testing
  • Laboratory testing services
  • Point-of-care testing
  • Workplace drug screening

Where Premier Biotech is headquartered

Location

Headquarters

HQ city
Minneapolis
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Premier Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Rapid Testing Products: Sales of point-of-care rapid drug testing products including OralTox oral fluid tests, Premier Bio-Cup and Premier Bio-Dip urine tests, and SAFE harm reduction test strips. Products are sold directly to employers, government agencies, and healthcare providers.
  2. Laboratory Testing Services: Confirmation testing services provided through CAP-accredited forensic and SAMHSA-certified laboratories in Minneapolis and Scottsdale. Supports regulated programs requiring chain-of-custody procedures.
  3. Technology and Software Services: Digital platform services including OT-Scan app for automated result interpretation and reporting, and Premier Biotech Services (PBS) for program administration, reporting, and background screening management.
  4. E-commerce Distribution: Through acquired companies like TransMed, Premier operates e-commerce platforms distributing testing products and laboratory supplies to over 1,000 direct customer accounts.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based pricing for enterprise and government customers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels3 records

Premier Biotech product offering

Product offering

Core offering

Premier Biotech manufactures and supplies rapid drug testing diagnostic devices including oral fluid and urine tests, complemented by digital interpretation tools and SAMHSA-certified/CAP-accredited laboratory confirmation services. The company serves employers, government agencies, healthcare providers, and background screening partners with an integrated testing ecosystem covering collection, interpretation, and confirmation from a single sample.

Product overview

Premier Biotech operates as an integrated drug and alcohol testing platform combining point-of-collection rapid tests with digital interpretation technology and laboratory confirmation services. The core product portfolio includes OralTox® (the #1 recognized rapid oral fluid testing brand), OT-Scan® (digital results reading and reporting app), Premier Bio-Cup and Premier Bio-Dip (rapid urine testing products), SAFE Harm Reduction Testing (adulterant detection strips), and Intercept i2he® (oral fluid collection device). These are supported by CAP-accredited forensic and SAMHSA-certified laboratory services in Minneapolis and Scottsdale, plus Premier Biotech Services (PBS) for end-to-end program management. The company has pursued an active acquisition strategy since partnering with Align Capital Partners in November 2022, acquiring Desert Tox LLC (SAMHSA-certified lab), National Test Systems (drug screening supplies), GH Solutions (point-of-care diagnostics distributor), and NexScreen/TransMed (point-of-care diagnostics and e-commerce testing supplies) to expand its footprint across workplace, government, and clinical markets.

Differentiator

Problem solved

Functional benefit

Brands

  • OralTox: Point-of-collection oral fluid test, recognized as the #1 brand in rapid oral fluid drug testing.
  • OT-Scan
  • Premier Bio-Cup
  • Premier Bio-Dip
  • SAFE
  • Intercept i2he
  • Premier Biotech Services (PBS)

Products and services

  • OralTox Rapid oral fluid drug test for use by employers, government agencies, healthcare providers, and background screening partners. Observed collection makes it nearly impossible to cheat, with results in minutes.
  • OT-Scan Digital interpretation app that objectively reads OralTox test results to reduce human error and produce defensible records. Used by collectors and program administrators.
  • Premier Bio-Cup Urine drug test cup for use in workplace, clinical, and government drug screening programs.
  • Premier Bio-Dip Urine drug test dip card for rapid screening applications.
  • SAFE Harm Reduction Testing Single-use fentanyl and xylazine test strip used for harm reduction testing.
  • Intercept i2he Oral fluid collection device used for laboratory-based oral fluid drug testing programs.
  • Premier Identification Kit (PIK) Identification kit used to support donor identification and chain-of-custody procedures in drug testing programs.
  • Lab Services SAMHSA-certified and CAP-accredited laboratory confirmation services that produce defensible results for regulated drug testing programs.
  • Premier Biotech Services (PBS) Customer service and logistics offering that simplifies test ordering and shipping for customers, with same-day shipping on most orders placed before 2 PM CT.

Quantifiable outcome

  • OT-Scan automatically interprets results, delivering consistent laboratory-style reporting within minutes
  • +1 more outcomes

Companies that use Premier Biotech

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles4 records

Premier Biotech technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Premier Biotech partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • NexScreencoreOthers · 1 June 2026NexScreen provides point-of-care diagnostic products across the United States, Australia, and New Zealand. The acquisition expands Premier's drug and alcohol testing platform with new distribution channels and international reach.
  • TransMedcoreOthers · 1 June 2026TransMed offers drug testing products and laboratory supplies to over 1,000 direct customer accounts through an e-commerce platform and international distributor network. The acquisition strengthens Premier's global footprint and online presence.
  • GH SolutionscoreOthers · 1 April 2026GH Solutions is a distributor of point-of-care diagnostic testing products serving government and workplace end markets across the United States. The acquisition increases Premier's customer base and broadens its solution portfolio.
  • National Test Systems (NTS)coreOthers · 1 November 2025National Test Systems is a provider of diagnostic drug screening supplies and services across the United States. The acquisition enhances Premier's customer base and strengthens its position in Government and Behavioral Health markets.
  • Desert Tox LLCcoreOthers · 1 June 2024Desert Tox is a SAMHSA-certified laboratory testing services provider acquired by Premier Biotech as its first add-on since being acquired by ACP in November 2022. Desert Tox serves various markets across the U.S. and aims to expand Premier's services and customer base.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Premier Biotech competitors and assessment

Company assessment

Emerging players

  • Chembio Diagnostics: Point-of-care diagnostic developer with rapid test products including drug testing panels. Comparable at the rapid test/device technology layer, though smaller and more emerging than Premier's established OralTox platform.

Direct peers

  • Confirm BioSciences: Direct competitor in rapid point-of-care drug testing products including oral fluid and urine panels marketed to employers and resellers. Comparable product overlap with Premier's Premier Bio-Cup/Bio-Dip and OralTox lines at the rapid test/distribution layer.
  • Drägerwerk (Dräger): Manufacturer of DrugTest 5000 and related oral fluid drug testing instruments widely used by law enforcement and workplace programs. Comparable on the rapid oral fluid instrument/consumable side of the market, particularly in criminal justice and European markets.
  • OraSure Technologies: Direct peer in rapid oral fluid drug testing — maker of Intercept Oral Fluid Drug Test and the Quantisal collection device used by many employers and criminal justice programs. Closest like-for-like competitor to OralTox and Intercept i2he, with an established federal/criminal justice footprint.
  • Redwood Toxicology Laboratory (acquired by ADM): Forensic and clinical toxicology lab serving workplace, legal, and clinical customers. Comparable to Premier's CAP-accredited/SAMHSA-certified lab services in Minneapolis and Scottsdale, competing on turnaround time, panel breadth, and chain-of-custody.
  • Psychemedics Corporation: Specialist in workplace drug testing — though focused on hair testing rather than oral fluid. Comparable as a niche, employer-focused drug testing provider competing for similar workplace and government customers with a differentiated specimen type.

Broad incumbents

  • Abbott (Rapid Diagnostics / Alere): Operates a large rapid diagnostics portfolio including point-of-care drug testing products (e.g., SoToxa oral fluid test). Comparable as a competing rapid oral fluid platform with deeper R&D and global distribution, though drug testing is one of many diagnostic categories within Abbott.
  • Quest Diagnostics: Largest U.S. clinical laboratory operator with a dedicated employer services/workplace drug testing business (Quest Diagnostics Employer Solutions). Comparable because it serves the same workplace and clinical drug testing buyers through a national lab network, though its scale and breadth vastly exceed Premier Biotech.
  • Thermo Fisher Scientific (Pharmaco / Clinical Diagnostics): Operates clinical and forensic toxicology testing services (including its Pharmaco and CEDIA toxicology franchises) that compete with Premier's lab confirmation services. Comparable on lab-based drug confirmation, with substantially broader life-sciences scale.
  • Laboratory Corporation of America (Labcorp): National clinical laboratory with employer drug testing services and SAMHSA-certified confirmation capabilities. Comparable on the lab confirmation side of Premier's integrated workflow, though Labcorp competes at much broader scale across routine clinical diagnostics as well.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Premier Biotech social profiles

Digital presence

Premier Biotech compliance and trust

Trust signal

Compliance12 records

Premier Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Premier Biotech leadership team

Management profile

Number of profiles

Profiles2 records

Premier Biotech subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Premier Biotech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Premier Biotech M&A and investment

M&A and investment

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Premier Biotech

What does Premier Biotech do?

Premier Biotech manufactures and supplies rapid drug testing diagnostic devices including oral fluid and urine tests, complemented by digital interpretation tools and SAMHSA-certified/CAP-accredited laboratory confirmation services. The company serves employers, government agencies, healthcare providers, and background screening partners with an integrated testing ecosystem covering collection, interpretation, and confirmation from a single sample.

Is Premier Biotech a public or private company?

Premier Biotech is a private company. It is classified as private equity controlled and is currently operating.

When was Premier Biotech founded?

Premier Biotech was founded in 2006. It employs 51 to 100 people.

Where is Premier Biotech based?

Premier Biotech is headquartered in Minneapolis, United States, in the North America region.

How does Premier Biotech make money?

Four revenue lines are on record. Rapid Testing Products are the primary driver. The others are laboratory Testing Services, technology and Software Services and E-commerce Distribution.

Who are Premier Biotech's main competitors?

Chembio Diagnostics is listed as an emerging player. Direct peers are Confirm BioSciences, Drägerwerk (Dräger), OraSure Technologies, Redwood Toxicology Laboratory (acquired by ADM) and Psychemedics Corporation. Broad incumbents are Abbott (Rapid Diagnostics / Alere), Quest Diagnostics, Thermo Fisher Scientific (Pharmaco / Clinical Diagnostics) and Laboratory Corporation of America (Labcorp).

Does Premier Biotech have an API?

No public API is recorded for Premier Biotech.

What industry is Premier Biotech in?

Premier Biotech's product category is Drug Testing Diagnostics. Its primary akta.pro industry code is HLAHAOAG, Drug-of-Abuse & Toxicology Rapid Tests (Urine/saliva panels), with a secondary code of HLAFAMAB, Clinical Chemistry & Immunoassay Laboratories. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizPremier Biotech Expands Drug Testing Platform With NexScreen and TransMed AcquisitionsPremier Biotech has acquired NexScreen and TransMed, expanding its drug and alcohol testing platform across healthcare, government, and workplace markets with new distribution channels and international reach. NexScreen brings point-of-care diagnostic products and access to Australia and New Zealand markets, while TransMed adds over 1,000 direct customer accounts and a broad e-commerce catalog of testing products and laboratory supplies. The acquisitions mark Premier Biotech's seventh and eighth deals since partnering with Align Capital Partners in November 2022, continuing an active buy-and-build growth strategy in the diagnostics and compliance testing industry.YahooPremier Biotech Broadens Product Portfolio With NexScreen and TransMed AcquisitionsPremier Biotech, a drug and alcohol testing solutions provider backed by Align Capital Partners, announced the acquisitions of NexScreen and TransMed to expand its global footprint and product portfolio. NexScreen provides point-of-care diagnostic testing across the United States, Australia and New Zealand, while TransMed offers drug testing products and laboratory supplies to over 1,000 direct customer accounts through an e-commerce platform and international distributor network. These acquisitions represent Premier's seventh since partnering with ACP in November 2022, as the company continues to pursue additional growth opportunities through acquisitions.FinancialContent Business PagePremier Biotech Broadens Product Portfolio With NexScreen and TransMed AcquisitionsAlign Capital Partners-backed Premier Biotech announced the acquisitions of NexScreen and TransMed to expand its drug and alcohol testing solutions business, with NexScreen providing point-of-care diagnostics across the US, Australia, and New Zealand, and TransMed serving over 1,000 direct customer accounts through its e-commerce platform. The acquisitions strengthen Premier's global footprint, product portfolio, and online presence while deepening its reach in healthcare, government, and workplace markets. With these additions, Premier Biotech has now completed seven acquisitions since partnering with ACP in November 2022, as part of its ongoing growth strategy.citybizPremier Biotech Acquires GH Solutions to Expand Testing Solutions PortfolioPremier Biotech, backed by private equity firm Align Capital Partners, has acquired GH Solutions, a distributor of point-of-care diagnostic testing products serving government and workplace end markets across the United States. The acquisition increases Premier's customer base and broadens its solution portfolio while providing GH's existing customers access to Premier's full product line including oral fluid testing, laboratory services, and technology solutions. This marks Premier's fifth acquisition since partnering with Align Capital Partners in November 2022, continuing its stated growth strategy in the drug and alcohol testing industry.Business Wire BlogPremier Biotech Adds Scale in Point-of-Care Testing with GH Solutions AcquisitionAlign Capital Partners-backed Premier Biotech has acquired GH Solutions, a distributor of point-of-care diagnostic testing products serving government and workplace end markets across the United States. The acquisition increases Premier's customer base and expands the solutions it can offer, with GH's long-tenured customer portfolio cited as a key asset in the deal. Premier CEO Matt Michalik called it a pivotal step in the company's growth journey and noted significant cross-sell potential, while this marks Premier's fifth acquisition since partnering with ACP in November 2022.openPR.comEmerging Sub-Segments Transforming the Drug Screening Market LandscapeThe drug screening market is projected to grow to $19.2 billion by 2030, representing a compound annual growth rate of 14.5%, driven by advances in AI-powered screening analytics, portable testing devices, and stricter regulatory compliance. In June 2024, Premier Biotech acquired Desert Tox, LLC to strengthen its laboratory testing capacity and expand its reach in the US oral-fluid drug testing market. In February 2025, Canadian firm Neopharma Technologies partnered with US-based Impairment Science to integrate NEOVAULT digital drug test reporting with AI-powered cognitive impairment assessment tools.MorningstarDrug of Abuse Testing Market Expands Across APAC, Europe, USA, and Saudi Arabia with Rising Workplace & Clinical ScreeningFuture Market Insights released a market analysis projecting the global Drug of Abuse Testing Market will grow from USD 5.41 billion in 2026 to USD 8.98 billion by 2036, representing a 5.2% CAGR, driven by regulatory compliance requirements and expanding workplace and clinical screening programs. The report highlights immunoassay-based screening integrated with chromatography-based confirmation methods as the dominant testing approach, with hospitals, diagnostic labs, and forensic facilities serving as primary end-users. Notable recent industry acquisitions include SCRAM Systems' purchase of PharmChem (August 2025) and Premier Biotech's acquisition of Desert Tox (June 2024), reflecting consolidation toward vertically integrated and compliance-focused testing ecosystems.Business Wire BlogPremier Biotech Appoints Industry Veteran Rod Weis as Chief Revenue Officer to Accelerate Market LeadershipPremier Biotech appointed Rod Weis as its new Chief Revenue Officer to lead the company's go-to-market strategy and accelerate growth in the drug and alcohol testing industry. Weis brings extensive experience from previous leadership roles at UKG and First Advantage, aiming to expand Premier's market position with its proprietary oral fluid solutions like OralTox® and OT-Scan®.Business Wire BlogPremier Acquires NTS to Accelerate Growth in Point-of-Care Drug Screening ServicesPremier Biotech acquired National Test Systems, a provider of rapid point-of-care drug screening supplies and services. NTS serves over 1,500 facilities, primarily in government and behavioral health, and Premier CEO Matt Michalik said the acquisition bolsters leadership in those channels. Premier will continue pursuing additional acquisitions.YahooPremier Acquires NTS to Accelerate Growth in Point-of-Care Drug Screening ServicesAlign Capital Partners’ Premier Biotech has acquired National Test Systems (NTS), a provider of rapid point-of-care diagnostic drug screening services, to accelerate growth in the Government and Behavioral Health markets. The acquisition expands Premier’s customer base to over 1,500 facilities and adds complementary testing solutions, with NTS CEO Andrew Panico remaining involved to support the transition. This marks Premier's fourth acquisition since partnering with Align Capital Partners in November 2022.